Carclo plc (CCEGF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Carclo plc (CCEGF) with AI Score 46/100 (Weak). Carclo plc specializes in fine tolerance injection molded plastic parts, serving the medical, aerospace, and electronics industries. Market cap: 0, Sector: Consumer cyclical.
Last analyzed: Mar 16, 2026Carclo plc (CCEGF) Consumer Business Overview
Carclo plc, established in 1924, manufactures fine tolerance injection molded plastic components across medical, aerospace, and electronics sectors. With a global presence spanning the UK, North America, and Asia, Carclo leverages its technical plastics and aerospace divisions to serve diverse industrial needs, maintaining a modest profit margin within the consumer cyclical industry.
Investment Thesis
Carclo plc presents a mixed investment thesis. The company's specialization in fine tolerance injection molded plastic parts for critical industries like medical and aerospace provides a degree of resilience. The Aerospace division, in particular, offers potential for stable, long-term contracts. However, the company's relatively small market capitalization ($0.05B) and modest profit margin (1.6%) suggest vulnerability to economic downturns and competitive pressures. A P/E ratio of 19.09 indicates that the stock is trading at a premium compared to its earnings. Key value drivers include the ability to secure and maintain contracts in the aerospace sector and the successful development of new applications for its technical plastics. Investors should closely monitor the company's ability to improve profitability and manage its cost structure. The absence of a dividend may deter some investors seeking regular income.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.05B reflects its small-cap status within the consumer cyclical sector.
- P/E ratio of 19.09 suggests the stock is trading at a premium relative to its earnings.
- Profit margin of 1.6% indicates relatively low profitability, requiring close monitoring of cost management.
- Gross margin of 56.8% demonstrates strong pricing power in its niche markets.
- Beta of 0.70 suggests lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Specialized expertise in fine tolerance injection molding.
- Strong presence in the aerospace industry.
- Global manufacturing footprint.
- Long-standing customer relationships.
Weaknesses
- Small market capitalization.
- Low profit margin.
- Dependence on cyclical industries.
- Limited brand recognition.
Catalysts
- Ongoing: Increased demand for medical devices requiring high-precision plastic components.
- Ongoing: Resurgence in the aerospace industry driving demand for specialist components.
- Upcoming: Potential strategic acquisitions to expand product portfolio and geographic reach.
- Ongoing: Investment in research and development to create new materials and technologies.
- Ongoing: Geographic expansion in Asia to tap into high-growth markets.
Risks
- Potential: Economic downturns impacting demand in cyclical industries.
- Ongoing: Increased competition from other manufacturers of plastic components.
- Potential: Fluctuations in raw material prices affecting profit margins.
- Potential: Technological obsolescence requiring continuous innovation.
- Ongoing: Limited liquidity and higher volatility due to OTC market listing.
Growth Opportunities
- Expansion in the medical device market: The increasing demand for sophisticated medical devices presents a significant growth opportunity for Carclo's Technical Plastics division. As medical technology advances, the need for high-precision plastic components will continue to rise. Carclo can leverage its expertise in fine tolerance injection molding to capture a larger share of this market. The global medical device market is projected to reach $600 billion by 2028, providing a substantial runway for growth. Timeline: Ongoing.
- Increased demand in the aerospace sector: The aerospace industry is experiencing a resurgence, driven by increased air travel and defense spending. Carclo's Aerospace division is well-positioned to benefit from this trend. The company's ability to provide specialist components for both commercial and military aircraft creates a stable and growing revenue stream. The global aerospace market is expected to grow at a rate of 4-5% annually over the next decade. Timeline: Ongoing.
- Geographic expansion in Asia: The Asian market, particularly China and India, offers significant growth potential for Carclo. These regions are experiencing rapid economic growth and increasing demand for high-quality plastic components and aerospace parts. Carclo can expand its presence in Asia through strategic partnerships and investments in local manufacturing facilities. This expansion can diversify its revenue base and reduce its reliance on mature markets. Timeline: 2-3 years.
- Development of new materials and technologies: Investing in research and development to create new materials and technologies can provide Carclo with a competitive edge. This includes exploring advanced polymers and molding techniques that can improve the performance and durability of its products. By staying at the forefront of technological innovation, Carclo can attract new customers and expand its market share. Timeline: Ongoing.
- Strategic acquisitions: Carclo can pursue strategic acquisitions to expand its product portfolio and geographic reach. This includes acquiring companies with complementary technologies or access to new markets. Acquisitions can accelerate Carclo's growth and enhance its competitive position. Careful due diligence and integration are essential for successful acquisitions. Timeline: 3-5 years.
Opportunities
- Expansion in the medical device market.
- Growth in emerging markets.
- Development of new materials and technologies.
- Strategic acquisitions.
Threats
- Economic downturns.
- Increased competition.
- Fluctuations in raw material prices.
- Technological obsolescence.
Competitive Advantages
- Specialized expertise in fine tolerance injection molding.
- Long-standing relationships with key customers in the medical and aerospace industries.
- Global presence with manufacturing facilities in multiple countries.
- Proprietary technologies and processes for producing high-precision components.
About CCEGF
Carclo plc, founded in 1924 and based in Ossett, United Kingdom, specializes in the manufacture and sale of fine tolerance injection molded plastic parts. The company operates through three primary segments: Technical Plastics, Aerospace, and Central. The Technical Plastics division focuses on producing high-precision plastic components for the medical, optical, diagnostics, and electronics industries. These components are critical in devices requiring exacting specifications and reliability. The Aerospace division provides specialist components, including control cables, machined components, aerofoil blading, streamline wires, and tie rods, catering to both commercial and military aerospace applications. The Central segment supports the operational and strategic needs of the other two divisions. Carclo's global footprint extends across the United Kingdom, North America, the Czech Republic, China, and India, enabling it to serve a diverse international clientele. The company's products are essential in various applications, ranging from medical devices and diagnostic equipment to aircraft and electronic products. Carclo's commitment to precision and quality has established it as a key supplier in its niche markets. The company's long history and specialized expertise provide a competitive edge in the fine tolerance plastics and aerospace components industries.
What They Do
- Manufactures fine tolerance injection molded plastic parts.
- Supplies components for the medical, optical, diagnostics, and electronics industries.
- Provides specialist components for the commercial and military aerospace industries.
- Offers control cables, machined components, aerofoil blading, streamline wires, and tie rods.
- Operates in the United Kingdom, North America, the Czech Republic, China, and India.
- Focuses on high-precision plastic components and aerospace parts.
Business Model
- Manufacturing and selling fine tolerance injection molded plastic parts.
- Providing specialist components to the aerospace industry.
- Generating revenue through long-term contracts and project-based sales.
- Operating through three segments: Technical Plastics, Aerospace, and Central.
Industry Context
Carclo plc operates within the auto parts industry, a segment of the broader consumer cyclical sector. This industry is influenced by trends in automotive manufacturing, aerospace, and medical device production. The competitive landscape includes companies specializing in precision components and plastic molding. Carclo differentiates itself through its focus on fine tolerance injection molding and its presence in both the technical plastics and aerospace markets. The industry is subject to fluctuations in demand based on economic cycles and technological advancements. Carclo's ability to adapt to changing market conditions and maintain its technological edge is crucial for its long-term success.
Key Customers
- Medical device manufacturers.
- Aerospace companies (both commercial and military).
- Electronics manufacturers.
- Optical and diagnostics equipment producers.
Financials
Chart & Info
Carclo plc (CCEGF) stock price: Price data unavailable
Latest News
-
Carclo's (LON:CAR) investors will be pleased with their splendid 288% return over the last three years
Yahoo! Finance: CCEGF News · Feb 9, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CCEGF.
Price Targets
Wall Street price target analysis for CCEGF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CCEGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Franciscus Lodewijk Paulus Doorenbosch
CEO
Franciscus Lodewijk Paulus Doorenbosch serves as the CEO of Carclo plc. His professional background includes extensive experience in manufacturing and engineering. He has held various leadership positions in multinational corporations, focusing on operational efficiency, strategic planning, and business development. His expertise spans across multiple industries, including automotive, aerospace, and electronics. He is known for his ability to drive growth and improve profitability through innovation and strategic partnerships. His leadership style emphasizes collaboration and a customer-centric approach.
Track Record: Since assuming the role of CEO, Franciscus Lodewijk Paulus Doorenbosch has focused on streamlining operations and improving the company's financial performance. Key initiatives include implementing cost-saving measures, expanding the company's presence in emerging markets, and investing in research and development. Under his leadership, Carclo has secured several significant contracts in the aerospace sector and has launched new products in the medical device market.
CCEGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Carclo plc may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of regulatory scrutiny as those listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and transparency.
- Potential for wider bid-ask spreads.
- Higher price volatility.
- Risk of delisting or suspension of trading.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any history of regulatory issues or fraud.
- Long operating history (incorporated in 1924).
- Global presence with operations in multiple countries.
- Established customer base in the medical and aerospace industries.
- Specialized expertise in fine tolerance injection molding.
- Employment of over 1000 people.
Common Questions About CCEGF
What does Carclo plc do?
Carclo plc specializes in the manufacture and sale of fine tolerance injection molded plastic parts, serving the medical, aerospace, and electronics industries. The company operates through three segments: Technical Plastics, Aerospace, and Central. The Technical Plastics division focuses on high-precision components for medical devices and diagnostic equipment, while the Aerospace division provides specialist components for commercial and military aircraft. Carclo's business model involves generating revenue through long-term contracts and project-based sales, leveraging its specialized expertise and global manufacturing footprint.
What do analysts say about CCEGF stock?
As of 2026-03-16, formal analyst ratings for CCEGF are limited due to its OTC listing and smaller market capitalization. However, key valuation metrics include a P/E ratio of 19.09 and a profit margin of 1.6%. Growth considerations revolve around the company's ability to capitalize on opportunities in the medical device and aerospace markets, as well as its success in expanding its geographic presence. Investors should closely monitor the company's financial performance and its ability to manage costs and maintain its competitive edge. The absence of a dividend may impact its appeal to income-seeking investors.
What are the main risks for CCEGF?
The main risks for Carclo plc include its exposure to cyclical industries, such as automotive and aerospace, which are sensitive to economic downturns. Increased competition from other manufacturers of plastic components and fluctuations in raw material prices can also negatively impact the company's profitability. Additionally, the company faces the risk of technological obsolescence, requiring continuous investment in research and development. Its OTC listing presents risks related to limited liquidity and higher volatility, potentially making it more difficult to trade the stock.
What are the key factors to evaluate for CCEGF?
Carclo plc (CCEGF) currently holds an AI score of 46/100, indicating low score. Key strength: Specialized expertise in fine tolerance injection molding.. Primary risk to monitor: Potential: Economic downturns impacting demand in cyclical industries.. This is not financial advice.
How frequently does CCEGF data refresh on this page?
CCEGF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CCEGF's recent stock price performance?
Recent price movement in Carclo plc (CCEGF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in fine tolerance injection molding.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CCEGF overvalued or undervalued right now?
Determining whether Carclo plc (CCEGF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CCEGF?
Before investing in Carclo plc (CCEGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than major exchange data.
- Analyst coverage may be limited due to the company's size and listing.